How does Jardiance or empagliflozin impact the treatment of chronic kidney disease
Jardiance or empagliflozin has been approved for the treatment of adults with chronic kidney disease in India. Discuss the effect of this medication on the disease.
- Jardiance or empagliflozin is a medication that belongs to a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors.
- It works by inhibiting the SGLT2 protein in the kidneys, which reduces the reabsorption of glucose and increases its excretion through the urine.
- In patients with chronic kidney disease, Jardiance has been shown to reduce the risk of kidney failure, end-stage kidney disease, and cardiovascular events.
- It can also improve kidney function and reduce the need for dialysis or kidney transplantation in some patients.
- Jardiance has been found to lower blood pressure and reduce the risk of heart failure in patients with chronic kidney disease, which are common complications of the condition.
- It is usually used in combination with other medications for the management of diabetes or high blood pressure in patients with chronic kidney disease.
- Jardiance is generally well tolerated, but it can cause side effects such as urinary tract infections, genital infections, and increased urination.
- It is important to consult a healthcare professional before starting Jardiance to determine if it is suitable for individual patients and to monitor kidney function during treatment.
Answered
a year ago